MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity

Oncogene

Volumn 35, Issue 4, 2016, Pages 448-458

  Xue, J ^a,b,c   Chi, Y ^a,b   Chen, Y ^a,b,d   Huang, S ^a,b   Ye, X ^a   Niu, J ^c   Wang, W ^c   Pfeffer, L M ^c   Shao, Z M ^a,b   Wu, Z H ^c   Wu, J ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CASPASE 8; FBXO11 PROTEIN; MICRORNA; MICRORNA 621; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PACLITAXEL; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; F BOX PROTEIN; FBXO11 PROTEIN, HUMAN; MIRN621 MICRORNA, HUMAN; PROTEIN ARGININE METHYLTRANSFERASE; TP53 PROTEIN, HUMAN;

ADJUVANT THERAPY; ADULT; ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELLULAR STRESS RESPONSE; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ECTOPIC EXPRESSION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; MCF 7 CELL LINE; MIDDLE AGED; MOUSE; NEDDYLATION; NONHUMAN; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN FUNCTION; TREATMENT RESPONSE; TUMOR MODEL; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CLINICAL TRIAL; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME; TUMOR CELL LINE;

ADULT; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CELL LINE, TUMOR; F-BOX PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE, INBRED BALB C; MICRORNAS; MIDDLE AGED; PACLITAXEL; PROTEIN-ARGININE N-METHYLTRANSFERASES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955666814     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.96     Document Type: Article

References (50)

1. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M et al. Effect of screening and adjuvant therapy on mortality from breast cancer. New Engl J Med 2005; 353: 1784-1792.
2. Dieras V, Fumoleau P, Romieu G, Tubiana-Hulin M, Namer M, Mauriac L et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004; 22: 4958-4965.
3. Iwata H, Sato N, Masuda N, Nakamura S, Yamamoto N, Kuroi K et al. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Jpn J Clinical Oncol 2011; 41: 867-875.
4. Lawrence G, Crawford J, Sherman F. Evaluating neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2002; 20: 2906-2907.
5. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456-1466.
6. Nowak AK, Wilcken NR, Stockler MR, Hamilton A, Ghersi D. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 2004; 5: 372-380.
7. Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 2014; 4: 232-245.
8. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-5312.
9. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11: 174-183.
10. Borst P, Wessels L. Do predictive signatures really predict response to cancer chemotherapy? Cell Cycle 2010; 9: 4836-4840.
11. Lee JK, Coutant C, Kim YC, Qi Y, Theodorescu D, Symmans WF et al. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 2010; 16: 711-718.
12. Weigelt B, Pusztai L, Ashworth A, Reis-Filho JS. Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol 2012; 9: 58-64.
13. Thuerigen O, Schneeweiss A, Toedt G, Warnat P, Hahn M, Kramer H et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 2006; 24: 1839-1845.
14. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006; 24: 4236-4244.
15. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 2010; 16: 5351-5361.
16. Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005; 123: 631-640.
17. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001; 294: 853-858.
18. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
19. Shivdasani RA. MicroRNAs: regulators of gene expression and cell differentiation. Blood 2006; 108: 3646-3653.
20. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013; 12: 847-865.
21. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Therapeut 2008; 7: 1-9.
22. Pan YZ, Morris ME, Yu AM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 2009; 75: 1374-1379.
23. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of proapoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 2010; 285: 21496-21507.
24. Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z et al. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PloS One 2012; 7: e34210.
25. Chen XS, Nie XQ, Chen CM, Wu JY, Wu J, Lu JS et al. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol 2010; 21: 961-967.
26. Bonnefoi H, Litiere S, Piccart M, Macgrogan G, Fumoleau P, Brain E et al. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Ann Oncol 2014; 25: 1128-1136.
27. Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr. et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 2012; 30: 3960-3966.
28. Chen Y, Chen C, Yang B, Xu Q, Wu F, Liu F et al. Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy. Cancer Lett 2011; 302: 63-68.
29. Wu X, Watson M. CORNA: testing gene lists for regulation by microRNAs. Bioinformatics 2009; 25: 832-833.
30. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26: 2157-2165.
31. Powell E, Piwnica-Worms D, Piwnica-Worms H. Contribution of p53 to metastasis. Cancer Discov 2014; 4: 405-414.
32. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009; 458: 1127-1130.
33. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr., Sjoblom T et al. The colorectal microRNAome. Proc Natl Acad Sci USA 2006; 103: 3687-3692.
34. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 2011; 305: 1873-1881.
35. Abbas T, Mueller AC, Shibata E, Keaton M, Rossi M, Dutta A. CRL1-FBXO11 promotes Cdt2 ubiquitylation and degradation and regulates Pr-Set7/Set8-mediated cellular migration. Mol Cell 2013; 49: 1147-1158.
36. Skaar JR, Pagan JK, Pagano M. Mechanisms and function of substrate recruitment by F-box proteins. Nat Rev Mol Cell Biol 2013; 14: 369-381.
37. Abida WM, Nikolaev A, Zhao W, Zhang W, Gu W. FBXO11 promotes the Neddylation of p53 and inhibits its transcriptional activity. J Biol Chem 2007; 282: 1797-1804.
38. Mulrane L, McGee SF, Gallagher WM, O'Connor DP. miRNA dysregulation in breast cancer. Cancer Res 2013; 73: 6554-6562.
39. Skawran B, Steinemann D, Becker T, Buurman R, Flik J, Wiese B et al. Loss of 13q is associated with genes involved in cell cycle and proliferation in dedifferentiated hepatocellular carcinoma. Mod Pathol 2008; 21: 1479-1489.
40. Duan S, Cermak L, Pagan JK, Rossi M, Martinengo C, di Celle PF et al. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature 2012; 481: 90-93.
41. Yang CH, Pfeffer SR, Sims M, Yue J, Wang Y, Linga VG et al. The oncogenic microRNA-21 inhibits the tumor suppressive activity of FBXO11 to promote tumorigenesis. J Biol Chem 2015; 290: 6037-6046.
42. Zheng H, Shen M, Zha YL, Li W, Wei Y, Blanco MA et al. PKD1 phosphorylation-dependent degradation of SNAIL by SCF-FBXO11 regulates epithelial-mesenchymal transition and metastasis. Cancer Cell 2014; 26: 358-373.
43. Yang F, Sun L, Li Q, Han X, Lei L, Zhang H et al. SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities. EMBO J 2012; 31: 110-123.
44. Dhami GK, Liu H, Galka M, Voss C, Wei R, Muranko K et al. Dynamic methylation of Numb by Set8 regulates its binding to p53 and apoptosis. Mol Cell 2013; 50: 565-576.
45. Walerych D, Napoli M, Collavin L, Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 2012; 33: 2007-2017.
46. Xirodimas DP, Saville MK, Bourdon JC, Hay RT, Lane DP. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 2004; 118: 83-97.
47. Li L, Wang M, Yu G, Chen P, Li H, Wei D et al. Overactivated neddylation pathway as a therapeutic target in lung cancer. J Natl Cancer Inst 2014; 106: dju083.
48. Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di GH et al. Identification of the functional role of AF1Q in the progression of breast cancer. Breast Cancer Res Treat 2008; 111: 65-78.
49. Li JY, Ou ZL, Yu SJ, Gu XL, Yang C, Chen AX et al. The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer. Breast Cancer Res Treat 2012; 131: 837-848.
50. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007; 4: 721-726.